Teva Pharmaceutical Industries Limited Share Price TEL AVIV STOCK EXCHANGE
Stocks
TEVA
IL0006290147
Pharmaceuticals
OTC Markets Traded|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 9,533.00 ILa | -0.88% |
|
+0.03% | -5.52% |
| 07-09 | Teva Pharmaceuticals Obtains Rights to Commercialize Polpharma's Biosimilar Candidate to Ocrevus | MT |
| 07-09 | Teva, Samsung Bioepis Partner to Commercialize Eylea Biosimilar Opuviz in Canada | MT |
| Market Cap | 35.11B 0 30.88B 28.68B 26.38B 49.47B 3,400B 50.36B 343B 134B 1,658B 132B 129B 5,753B | P/E 2026 * |
37.2x | P/E 2027 * | 16.4x |
|---|---|---|---|---|---|
| Enterprise Value | 46.27B 0 40.69B 37.8B 34.77B 65.21B 4,481B 66.37B 452B 176B 2,186B 174B 170B 7,582B | EV / Sales 2026 * |
2.78x | EV / Sales 2027 * | 2.53x |
| Free-Float |
88.61% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Teva Pharmaceutical Industries Limited
| 1 day | -0.88% | ||
| 1 week | +0.03% | ||
| Current month | -3.09% | ||
| 1 month | +1.64% | ||
| 3 months | -1.29% | ||
| 6 months | -3.94% | ||
| Current year | -5.52% |
| 1 week | 9,396 |  | 9,930 |
| 1 month | 9,396 | | 10,730 |
| Current year | 8,860 | | 11,350 |
| 1 year | 5,305 | | 11,350 |
| 3 years | 3,002 | | 11,350 |
| 5 years | 2,383 | | 11,350 |
| 10 years | 2,175 | | 21,200 |
| Manager | Title | Age | Since |
|---|---|---|---|
Richard Francis
CEO | Chief Executive Officer | 57 | 31/12/2022 |
Eli Kalif
DFI | Director of Finance/CFO | 53 | 21/12/2019 |
Matthew Shields
COO | Chief Operating Officer | 52 | 02/06/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
Amir Elstein
BRD | Director/Board Member | 69 | 31/12/2008 |
Sol Barer
CHM | Chairman | 78 | 05/02/2017 |
Rosemary Crane
BRD | Director/Board Member | 65 | 31/08/2015 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.88% | +0.03% | - | - | 35.11B | |
| +1.63% | +1.15% | +48.04% | +157.48% | 1,037B | |
| +1.14% | +3.38% | +52.83% | +51.06% | 615B | |
| +1.08% | +0.57% | +34.26% | +78.68% | 448B | |
| +5.14% | +5.40% | +33.75% | +27.79% | 326B | |
| +1.85% | +3.57% | +37.09% | +40.59% | 293B | |
| -0.11% | +0.48% | +18.87% | +17.70% | 264B | |
| +0.25% | -4.62% | -27.66% | -41.76% | 216B | |
| +0.68% | -0.87% | +19.13% | +56.47% | 198B | |
| -0.12% | -4.53% | +14.58% | +67.55% | 162B | |
| Average | +1.05% | +1.12% | +25.65% | +50.62% | 395.27B | |
| Weighted average by Cap. | +1.44% | +1.47% | +35.04% | +75.52% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 16.64B 0 14.63B 13.59B 12.5B 23.44B 1,611B 23.86B 163B 63.4B 786B 62.46B 61.1B 2,726B | 17.23B 0 15.16B 14.08B 12.95B 24.28B 1,669B 24.72B 168B 65.67B 814B 64.69B 63.29B 2,824B |
| Net income | 1.31B 0 1.15B 1.07B 984M 1.84B 127B 1.88B 12.79B 4.99B 61.84B 4.91B 4.81B 215B | 2.46B 0 2.17B 2.01B 1.85B 3.47B 239B 3.53B 24.07B 9.39B 116B 9.25B 9.05B 404B |
| Net Debt | 11.16B 0 9.82B 9.12B 8.39B 15.73B 1,081B 16.01B 109B 42.54B 527B 41.91B 41B 1,829B | 8.41B 0 7.39B 6.87B 6.32B 11.85B 814B 12.06B 82.13B 32.03B 397B 31.56B 30.88B 1,378B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 22/07/26 | ILA 9,533.00 | -0.88% | 1,061,041 |
| 21/07/26 | ILA 9,618.00 | -0.25% | 1,288,336 |
| 20/07/26 | ILA 9,642.00 | -0.96% | 759,073 |
| 17/07/26 | ILA 9,735.00 | -0.41% | 485,235 |
| 16/07/26 | ILA 9,775.00 | +2.57% | 1,284,861 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- TEVA Stock
- TEVA Stock
Select your edition
All financial news and data tailored to specific country editions
